wegovy glp 1 agonist Key Lessons for Ethical and Affordable Access to GLP-1 Drugs GLP-1 Drug Savings: A Complete
Description
Recent Developments: 2025: Eli Lilly received FDA approval for tirzepatide (Zepbound) as a treatment for moderate-to-severe obstructive sleep apnea in adults with obesity the first pharmacotherapy approved for this indication expanding tirzepatide's approved uses beyond metabolic conditions into a respiratory indication affecting over 30 million Americans and supported by SURMOUNT-OSA trial data showing 63% reduction in apnea-hypopnea index
Side effects and risks of oral GLP-1s Oral GLP-1s have similar side effects to injectable GLP-1s , with the most common ones being gastrointestinal in nature
Among these, 3,465 (9.8%) received GLP-1 RAs within 3 months post-transplant (Fig
That is more than triple the 3% of adults who reported doing so just two years prior in 2024
GLP-1 receptor agonists: a new treatment in Parkinsons disease
Clin Ther (2014) 36:84100.e9
